Thrivent Financial for Lutherans increased its position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 6.5% during the fourth quarter, Holdings Channel reports. The firm owned 2,620 shares of the biopharmaceutical company’s stock after buying an additional 160 shares during the period. Thrivent Financial for Lutherans’ holdings in Regeneron Pharmaceuticals were worth $962,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Alpha Windward LLC increased its position in Regeneron Pharmaceuticals by 11.6% in the third quarter. Alpha Windward LLC now owns 326 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 34 shares during the last quarter. Live Your Vision LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at $157,000. Blenheim Capital Management BV acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at $160,000. Global X Management Co. LLC increased its position in Regeneron Pharmaceuticals by 212.7% in the third quarter. Global X Management Co. LLC now owns 419 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 285 shares during the last quarter. Finally, Private Wealth Partners LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at $201,000. Institutional investors own 68.83% of the company’s stock.
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) opened at 373.00 on Friday. Regeneron Pharmaceuticals Inc has a 52-week low of $325.35 and a 52-week high of $452.96. The company has a market cap of $39.34 billion, a P/E ratio of 48.45 and a beta of 1.44. The stock’s 50 day moving average price is $374.30 and its 200-day moving average price is $378.96.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, February 9th. The biopharmaceutical company reported $3.04 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.03 by $0.01. The firm had revenue of $1.23 billion for the quarter, compared to analyst estimates of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The business’s revenue was up 11.7% on a year-over-year basis. During the same period in the previous year, the company posted $2.83 earnings per share. On average, equities analysts predict that Regeneron Pharmaceuticals Inc will post $12.93 earnings per share for the current fiscal year.
Several research analysts have weighed in on REGN shares. Leerink Swann set a $500.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, December 1st. Royal Bank of Canada set a $626.00 price target on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Monday, December 5th. Chardan Capital upgraded Regeneron Pharmaceuticals from a “sell” rating to a “neutral” rating and upped their price target for the stock from $300.00 to $350.00 in a research note on Monday, December 12th. Robert W. Baird restated a “positive” rating and issued a $379.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday, December 12th. Finally, Vetr downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating and set a $401.26 price target for the company. in a research note on Monday, December 12th. Fourteen equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $434.97.
In related news, major shareholder Sanofi acquired 87,298 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, January 11th. The shares were purchased at an average price of $369.71 per share, for a total transaction of $32,274,943.58. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 10.40% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.